Literature DB >> 12410087

Clinical outcomes in juvenile dermatomyositis.

A V Ramanan1, B M Feldman.   

Abstract

Juvenile dermatomyositis is a chronic inflammatory illness of unknown etiology that affects primarily muscle and skin. It has an incidence of 2-3 per 1,000,000, per year. The disease can affect other organ systems, including the gastrointestinal tract, lungs, and heart. In addition, calcinosis is seen in one-third of patients. The mainstay of therapy is corticosteroids; some children require additional immunosuppressive agents because of corticosteroid resistance or intolerance. Functional outcomes have become good with modern treatments, but the disease remains chronic in a large number of children and sequelae are often seen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410087     DOI: 10.1097/00002281-200211000-00005

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  9 in total

1.  Clinical quiz: a pediatric case presenting with fever and diffuse myalgia.

Authors:  Alper Soylu; Yeşim Oztürk; Belde Kasap; Nilüfer Akman; Mehmet Türkmen; Salih Kavukçu
Journal:  Rheumatol Int       Date:  2004-11-10       Impact factor: 2.631

Review 2.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 3.  Paediatric idiopathic inflammatory muscle disease: recognition and management.

Authors:  Clarissa A Pilkington; Lucy R Wedderburn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Juvenile dermatomyositis with Sjögren's syndrome.

Authors:  M V Holmes; Y Ioannou; C Borysiewicz; D Sen
Journal:  Clin Rheumatol       Date:  2007-12-21       Impact factor: 2.980

5.  Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.

Authors:  Abdolreza Malek; Seyed-Reza Raeeskarami; Vahid Ziaee; Yahya Aghighi; Mohamad-Hassan Moradinejad
Journal:  Clin Rheumatol       Date:  2014-05-31       Impact factor: 2.980

6.  Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.

Authors:  Anjali Patwardhan; Robert Rennebohm; Igor Dvorchik; Charles H Spencer
Journal:  Pediatr Rheumatol Online J       Date:  2012-09-20       Impact factor: 3.054

7.  Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.

Authors:  C H Spencer; K Rouster-Stevens; H Gewanter; G Syverson; R Modica; K Schmidt; H Emery; C Wallace; S Grevich; K Nanda; Y D Zhao; S Shenoi; S Tarvin; S Hong; C Lindsley; J E Weiss; M Passo; K Ede; A Brown; K Ardalan; W Bernal; M L Stoll; B Lang; R Carrasco; C Agaiar; L Feller; H Bukulmez; R Vehe; H Kim; H Schmeling; D Gerstbacher; M Hoeltzel; B Eberhard; R Sundel; S Kim; A M Huber; A Patwardhan
Journal:  Pediatr Rheumatol Online J       Date:  2017-06-13       Impact factor: 3.054

8.  Abatacept in the Treatment of Juvenile Dermatomyositis-Associated Calcifications in a 16-Year-Old Girl.

Authors:  Sukesh Sukumaran; Vini Vijayan
Journal:  Case Rep Rheumatol       Date:  2020-05-28

9.  Calcinosis Universalis of the Elbow: A Rare Case with Classical Presentation.

Authors:  Sebastian Philipp Boelch; Thomas Barthel; Sascha Goebel; Maximilian Rudert; Piet Plumhoff
Journal:  Case Rep Orthop       Date:  2015-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.